TORONTO, Oct. 10, 2025 — Leads & Copy — Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, has announced a new distribution partnership with Renellence, a Canadian company specializing in aesthetic medicine. This collaboration aims to strengthen Croma’s presence in the Canadian market, building upon the company’s established presence in the region.
Under the agreement, Renellence will distribute the MDR-approved hyaluronic acid filler range Croma saypha® in Canada. The partnership will also focus on strengthening medical education and training initiatives for Canadian healthcare professionals.
According to Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH, Canada has always been an important market for Croma-Pharma. Aria Moghimi, Chief Executive Officer of Renellence, stated that the partnership positions Renellence to play a defining role in shaping the future of aesthetics in Canada.
Croma-Pharma GmbH specializes in the production of hyaluronic acid syringes and distributes its own aesthetic portfolio in more than 80 markets worldwide. Renellence Inc. focuses on products that meet the highest international standards and serves as a platform for advancing innovation and delivering solutions to Canadian practitioners.
Contact: Andreas Prinz, Chief Executive Officer, Croma-Pharma GmbH.
Source: Croma Pharma
